Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children

PLEASE NOTE, THESE DATA ARE ALSO REFERRED TO IN TWO OTHER ARTICLES. PLEASE SEE http://dx.doi.org/10.1136/bmj.g2547 AND http://dx.doi.org/10.1136/bmj.g2545 FOR MORE INFORMATION.

Background: Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating and preventing seasonal and pandemic influenza. They are used clinically worldwide. Objectives: To describe the potential benefits and harms of NIs for influenza in all age groups by reviewing all clinical study reports of published and unpublished randomised, placebo-controlled trials and regulatory comments. Search methods: We searched trial registries, electronic databases (to 22 July 2013) and regulatory archives, and corresponded with manufacturers to identify all trials. We also requested clinical study reports. We focused on the primary data sources of manufacturers but we checked that there were no published randomised controlled trials (RCTs) from non-manufacturer sources by running electr...